Budget Impact Analysis of the FreeStyle Libre Flash Continuous Glucose Monitoring System® in Patients with Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus with Multiple Daily Insulin Injections in Argentina

Palacios, Alfredo; Cairoli, Federico Rodríguez; Balan, Dario; Rojas‐Roque, Carlos; Moreno-López, Carolina; Braun, Barbara I.; Augustovski, Federico; Andrés, Paúl; Bardach, Ariel

doi:10.1007/s40258-023-00800-0

Cited by 2 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each third-party payer obtains its own acquisition cost. For this reason, the applied health economics studies conducted in the country could follow two approaches [ 36 , 37 ]: i) to use the retail price (PVP) or ii) to use the ex-factory price that is calculated as the PVP divided by 1.7545. The latest could be considered a more "realistic" approach, closer to the actual prices paid by different third-party payers.…”

Section: Discussionmentioning

confidence: 99%

“…Drawing on Argentina’s challenges related to high-inflation rates, we followed the approach used in other local BIAs [ 36 , 38 ] and decided to exclude inflationary factors from our results. It is important to mention that the ISPOR Task Force guidelines for BIA recommended inflation adjustments but did not provide specific guidance about how to handle this issue in practice.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina

Palacios,

Espinola,

Gonzalez

et al. 2024

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Objective This study aimed to estimate the budget impact of the incorporation of venetoclax for the treatment of patients with Acute Myeloid Leukemia (AML) over 75 years of age or those with comorbidities and contraindications for the use of intensive chemotherapy, from the perspective of the social security and the private third-party payers in Argentina. Methods A budget impact model was adapted to estimate the cost difference between the current scenario (azacitidine, decitabine and low doses of cytarabine) and the new scenario (incorporation of venetoclax) for a third-party payer over a time horizon of three years. Input parameters were obtained from a literature review, validated or complemented by expert opinion using a modified Panel Delphi approach. All direct medical costs were estimated by the micro-costing approach and were expressed in US dollars (USD) as of September 2020 (1 USD = 76.18 Argentine pesos). Results For a third-party payer with a cohort of 1,000,000 individuals covered, incorporating venetoclax was associated with an average budget impact per-member per-month (PMPM) of $0.11 USD for the social security sector and $0.07 USD for the private sector. The duration of treatment with venetoclax was the most influential parameter in the budget impact results. Conclusion The introduction of venetoclax was associated with a positive and slight budget impact. These findings are informative to support policy decisions aimed to expand the current treatment landscape of AML.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina

Palacios,

Espinola,

Gonzalez

et al. 2024

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England

Alsaif,

Farhat,

Blumer

et al. 2024

Health Econ Rev

View full text Add to dashboard Cite

Introduction In 2022, updated guidance from NICE expanded the options for self-monitoring of blood glucose for patients with type 2 diabetes (T2DM), to include continuous glucose monitoring (CGM). In this budget impact analysis, the cost impact of CGM was compared with traditional self-monitoring of blood glucose (SMBG) in adults with T2DM over 1 year from the commissioner perspective in England. Research Design and methods The NICE-eligible T2DM cohort was split into 4 subgroups to enable nuanced costing by insulin administration frequency: basal human insulin, premixed insulin, basal-bolus insulin and bolus insulin. The model’s cost components comprised mild and severe hypoglycaemia (SH), diabetic ketoacidosis (DKA), consumables and healthcare resource utilisation in primary and secondary care. Results The introduction of CGM is estimated to be cost additive by approximately £4.6 million in the basecase, driven by increased spending on the CGM device. Overall, healthcare activity was reduced by approximately 20,000 attendances, due to fewer SH and DKA episodes in the CGM arm. General Practitioner (GP) practice-based activity is expected to drop after the first year as patients requiring CGM training is reduced. The budget impact could be neutralised if the CGM sensor was discounted by 13.2% (£29.76 to £25.83). Conclusions CGM may result in increased spending in the NICE-eligible T2DM cohort but is expected to reduce demand on secondary care services and GP time. These findings may be of interest to local decision-makers who wish to resolve the COVID-19 backlog with transformational investment in primary care to reduce secondary care activity.

show abstract

Budget Impact Analysis of the FreeStyle Libre Flash Continuous Glucose Monitoring System® in Patients with Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus with Multiple Daily Insulin Injections in Argentina

Cited by 2 publications

References 37 publications

Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina

Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina

Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England

Contact Info

Product

Resources

About